• About us
• Contact

Advertisement

Organisation › Details

Luminex Corporation (Nasdaq: LMNX)

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP(R) technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex or xMAP(R) can be obtained on the Internet at http://www.luminexcorp.com. *

 

	Start	1995-05-01 established
	Group	DiaSorin (Group)
	Industry	BIOTECH
	Industry 2	xMAP® technology (Luminex)
	Street	12212 Technology Boulevard
	City	78727 Austin, TX
	Tel	+1-512-219-8020
		Address record changed: 2020-12-02
Basic data	Employees	F: 1,001 to 5,000 (2021-04-11)
	Currency	USD
	Annual sales	417,000,000 (revenue (2020) 2020-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for DiaSorin (Group)

• [1] Lumicks Technologies B.V.. (8/17/21). "Press Release: Lumicks Appoints Paul Wheeler to Leadership Team as Chief Commercial Officer to Drive New Business Growth". Amsterdam....
• [2] Qiagen N.V.. (11/27/19). "Press Release: Qiagen and DiaSorin Receive FDA Approval for the Liaison QuantiFERON-TB Gold Plus Test on Liaison Platforms and Begin Commercial Launch". Germantown, MD, Hilden & Saluggia....
• [3] Qiagen N.V.. (6/5/19). "Press Release: Qiagen and DiaSorin Collaborate on Novel QuantiFERON-based Test with Breakthrough Potential for Earlier Detection of Lyme Disease". Germantown, MD, Hilden & Saluggia....
• [4] Qiagen N.V.. (9/17/18). "Press Release: Qiagen and DiaSorin Launch Automated Testing for Latent TB Infection with QuantiFERON-TB Gold Plus Technology on Widely Used Liaison Platforms". Hilden & Saluggia....
• [5] DiaSorin S.p.A.. (5/8/18). "Press Release: The DiaSorin Group Reports Growth in Revenues and Profitability in the First Quarter 2018". Saluggia....
• [6] DiaSorin S.p.A.. (11/9/17). "Press Release: Growth in Revenues and Net Profit in Q3 2017". Saluggia....
• [7] DiaSorin S.p.A.. (7/25/17). "Press Release: DiaSorin to Acquire ELISA Immunodiagnostic Business Portfolio and Associated Assets from Siemens Healthineers". Saluggia....
• [8] Tecan Group Ltd.. (6/23/17). "Press Release: DiaSorin and Tecan to Collaborate in New Platform Development". Saluggia & Männedorf....
• [9] DiaSorin S.p.A.. (6/22/17). "Press Release: DiaSorin and Qiagen Sign Collaboration to Expand Liaison Test Menu througth Adoption of Select Qiagen Assays". Saluggia, Hilden & Germantown, MD....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.